Moonlake Immunotherapeutics Stock Performance
| MLTX Stock | USD 39.09 0.58 1.46% |
The company secures a Beta (Market Risk) of 0.65, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MoonLake Immunotherapeuti's returns are expected to increase less than the market. However, during the bear market, the loss of holding MoonLake Immunotherapeuti is expected to be smaller as well. At this point, MoonLake Immunotherapeuti has a negative expected return of -0.49%. Please make sure to verify MoonLake Immunotherapeuti's information ratio, kurtosis, as well as the relationship between the Kurtosis and period momentum indicator , to decide if MoonLake Immunotherapeuti performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days MoonLake Immunotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.23) | Five Day Return (0.75) | Year To Date Return (25.95) | Ten Year Return 278.17 | All Time Return 278.17 |
1 | When the Price of Talks, People Listen - Stock Traders Daily | 01/27/2025 |
2 | Disposition of 56065 shares by Santos Da Silva Jorge of MoonLake Immunotherapeuti at 55.0 subject to Rule 16b-3 | 01/30/2025 |
3 | MoonLake Immunotherapeutics Reports Q4 EPS of -0. ... | 02/26/2025 |
4 | Needham Company LLC Increases MoonLake Immunotherapeutics Price Target to 66.00 | 02/27/2025 |
5 | Acquisition by Santos Da Silva Jorge of 95763 shares of MoonLake Immunotherapeuti subject to Rule 16b-3 | 03/03/2025 |
6 | Acquisition by Matthias Bodenstedt of 95763 shares of MoonLake Immunotherapeuti subject to Rule 16b-3 | 03/04/2025 |
7 | MoonLake Immunotherapeutics Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks | 03/11/2025 |
8 | Disposition of 3027483 shares by Santos Da Silva Jorge of MoonLake Immunotherapeuti subject to Rule 16b-3 | 03/14/2025 |
9 | MoonLake Immunotherapeutics Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks | 03/17/2025 |
10 | MoonLake Immunotherapeutics Earns Outperform Rating from Analysts at Royal Bank of Canada | 03/21/2025 |
| Begin Period Cash Flow | 451.2 B |
MoonLake |
MoonLake Immunotherapeuti Relative Risk vs. Return Landscape
If you would invest 5,440 in MoonLake Immunotherapeutics on December 26, 2024 and sell it today you would lose (1,473) from holding MoonLake Immunotherapeutics or give up 27.08% of portfolio value over 90 days. MoonLake Immunotherapeutics is currently does not generate positive expected returns and assumes 2.8411% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than MoonLake, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MoonLake Immunotherapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MoonLake Immunotherapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MoonLake Immunotherapeutics, and traders can use it to determine the average amount a MoonLake Immunotherapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1707
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MLTX |
Estimated Market Risk
| 2.84 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MoonLake Immunotherapeuti is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MoonLake Immunotherapeuti by adding MoonLake Immunotherapeuti to a well-diversified portfolio.
MoonLake Immunotherapeuti Fundamentals Growth
MoonLake Stock prices reflect investors' perceptions of the future prospects and financial health of MoonLake Immunotherapeuti, and MoonLake Immunotherapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MoonLake Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 2.07 B | ||||
| Shares Outstanding | 63.28 M | ||||
| Price To Book | 5.75 X | ||||
| EBITDA | (141.71 M) | ||||
| Net Income | (121.24 B) | ||||
| Cash And Equivalents | 92.71 M | ||||
| Cash Per Share | 2.51 X | ||||
| Total Debt | 2.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.51 X | ||||
| Book Value Per Share | 7.08 X | ||||
| Cash Flow From Operations | (116.59 B) | ||||
| Earnings Per Share | (1.89) X | ||||
| Market Capitalization | 2.57 B | ||||
| Total Asset | 477.93 B | ||||
| Retained Earnings | (235.59 B) | ||||
| Working Capital | 451.82 M | ||||
About MoonLake Immunotherapeuti Performance
Evaluating MoonLake Immunotherapeuti's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MoonLake Immunotherapeuti has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MoonLake Immunotherapeuti has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 87.4 K | 77.7 K | |
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.12) | (0.11) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.27) | (0.26) |
Things to note about MoonLake Immunotherapeuti performance evaluation
Checking the ongoing alerts about MoonLake Immunotherapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MoonLake Immunotherapeuti help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MoonLake Immunotherapeuti generated a negative expected return over the last 90 days | |
| MoonLake Immunotherapeuti has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (121.24 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| MoonLake Immunotherapeutics currently holds about 92.71 M in cash with (116.59 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: MoonLake Immunotherapeutics Earns Outperform Rating from Analysts at Royal Bank of Canada |
- Analyzing MoonLake Immunotherapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MoonLake Immunotherapeuti's stock is overvalued or undervalued compared to its peers.
- Examining MoonLake Immunotherapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MoonLake Immunotherapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MoonLake Immunotherapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MoonLake Immunotherapeuti's stock. These opinions can provide insight into MoonLake Immunotherapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.